**Core Concept**
The underlying principle being tested is the management of **hormone receptor-positive breast cancer** with metastasis, focusing on systemic treatment options that target **hormonal pathways**.

**Why the Correct Answer is Right**
Given the context of a hormone-dependent fungating carcinoma of the breast with lung secondaries, the treatment approach would involve **hormonal therapy** to control the growth of the cancer cells. This typically includes medications that either lower the levels of hormones such as estrogen, which can fuel the growth of hormone receptor-positive breast cancers, or block the receptors where these hormones bind.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because it is not specified, but typically, options that do not involve hormonal manipulation or are not standard treatments for hormone-dependent breast cancer would be incorrect.
**Option B:** Similarly, without specifics, any option not aligned with standard hormonal therapy for metastatic hormone receptor-positive breast cancer would be incorrect.
**Option D:** Incorrect for the same reason as options A and B, lacking alignment with standard treatment protocols for this condition.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that the treatment of hormone receptor-positive metastatic breast cancer often involves **aromatase inhibitors**, **selective estrogen receptor modulators (SERMs)**, or other forms of **endocrine therapy**, which can significantly improve outcomes by reducing estrogen's stimulatory effects on cancer cells.

**Correct Answer:** Not provided in the query, but typically, an answer involving **hormonal therapy** such as tamoxifen or an aromatase inhibitor would be correct.